DexCom stock surged +7.21% to $61.99 in mid-day trading after activist investor Elliott Management took a major stake and reached a cooperation agreement with the board. The company also announced a $1 billion share repurchase program during its 2026 Investor Day.
Elliott's Marc Steinberg expressed strong conviction in the CGM market's underpenetration and DexCom's growth potential. The company outlined 2030 goals including 67-69% gross margin and 29-30% operating margin.
Analysts remain bullish: Piper Sandler reiterated Buy with $75 target, Truist Securities with $80 target. The broader market declined, but DexCom outperformed sharply.












